SynthesisAdvances in therapy2017

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.

Erkki Soini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.